Figure 3.

Comparison of survival after MNC, CD133⁺, or placebo infusion in patients with decompensated cirrhosis. Survival (A) and complication-free survival (B) in three groups within 12 months of follow-up. One patient in the MNC group and one in the placebo group died and were excluded from the analysis (two deaths total). Hepatocellular carcinoma (HCC) and liver transplantation were considered complications. Two patients in the CD133⁺ group and one in the placebo group underwent liver transplantation. Furthermore, 1 patient in the MNC group developed HCC and was also excluded from the analysis. Abbreviation: MNC, mononuclear cell.